Equity Profile

IQV

IQVIA Holdings Inc.

Health CareLife Sciences Tools & Services$34.6B

Jul21Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

IQVIA Holdings Inc. operates in the health care sector, providing advanced analytics, technology solutions, and contract research services to the life sciences industry....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial measure of profitability and will indicate how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and drive sales in a competitive environment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IQV Q2-2026 Earnings Preview

Context

Company Snapshot

IQVIA Holdings Inc. operates in the health care sector, providing advanced analytics, technology solutions, and contract research services to the life sciences industry. As a key player in health care data and analytics, IQVIA helps companies improve patient outcomes and streamline drug development processes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.71%

Avg Stock Reaction

+2.48%

Last Quarter Recap

In Q1-2026, IQVIA reported an EPS of $2.90, exceeding estimates by 15.68%. The stock reacted positively, gaining 9.62% the following day.

Management Promises & Guidance

Focus on enhancing data analytics capabilities.
Commitment to expanding partnerships in the life sciences sector.
Plans to invest in technology to improve service delivery.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong track record of beating EPS estimates.

Bull Case

If IQVIA continues its trend of outperforming EPS estimates, it could see significant stock price appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, any signs of slowing growth or failure to meet expectations could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

Given IQVIA's history of beating EPS estimates, this number will be critical for investor sentiment.

What is the outlook for revenue growth in the upcoming quarters?

Investors will be keen to understand if the company can sustain its growth trajectory in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate IQVIA's ability to leverage its data analytics capabilities for sustained revenue growth, especially in light of recent industry trends.

Supporting Evidence

IQVIA has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent commentary from industry peers indicates a growing demand for data analytics in health care.

Key Risk

If revenue growth exceeds expectations, it could significantly alter market perceptions and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether IQVIA can maintain its strong earnings momentum amid market challenges.

Bull Confirmed If

An EPS of $3.00 or higher would confirm strong performance and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $2.50 could signal potential issues with growth or profitability, leading to a negative market response.

Pre-Earnings Positioning

Options Market

Implied Move

±16.03%

Historical Avg

±7.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.0% while IQV has averaged ±7.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

51.6%

Calls (204K)P/C Ratio: 0.32Puts (69K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IQVIA beats expectations, history suggests a stock increase of around 2.48%, confirming the company's strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 4.01%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$50,001.00–$100,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new data analytics partnerships and their expected impact on revenue.
2Any commentary on market trends affecting the life sciences sector.
3Insights into cost management strategies and their effect on margins.
4Discussion of future growth initiatives and areas of investment.
5Management's outlook on competitive pressures and how they plan to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

IQVIA Holdings Inc. operates in the health care sector, providing advanced analytics, technology solutions, and contract research services to the life sciences industry....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial measure of profitability and will indicate how well the company is managing costs and generating revenue.

N/A

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market share and drive sales in a competitive environment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

IQV Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+11.71%

Avg Stock Reaction

+2.48%

Last Quarter Recap

In Q1-2026, IQVIA reported an EPS of $2.90, exceeding estimates by 15.68%. The stock reacted positively, gaining 9.62% the following day.

Management Promises & Guidance

Focus on enhancing data analytics capabilities.
Commitment to expanding partnerships in the life sciences sector.
Plans to invest in technology to improve service delivery.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's strong track record of beating EPS estimates.

Bull Case

If IQVIA continues its trend of outperforming EPS estimates, it could see significant stock price appreciation, especially if revenue growth is also strong.

Bear Case

Conversely, any signs of slowing growth or failure to meet expectations could lead to a sharp decline in stock price, given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

Given IQVIA's history of beating EPS estimates, this number will be critical for investor sentiment.

What is the outlook for revenue growth in the upcoming quarters?

Investors will be keen to understand if the company can sustain its growth trajectory in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate IQVIA's ability to leverage its data analytics capabilities for sustained revenue growth, especially in light of recent industry trends.

Supporting Evidence

IQVIA has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent commentary from industry peers indicates a growing demand for data analytics in health care.

Key Risk

If revenue growth exceeds expectations, it could significantly alter market perceptions and drive the stock higher.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether IQVIA can maintain its strong earnings momentum amid market challenges.

Bull Confirmed If

An EPS of $3.00 or higher would confirm strong performance and likely lead to a positive market reaction.

Bear Confirmed If

An EPS below $2.50 could signal potential issues with growth or profitability, leading to a negative market response.

Pre-Earnings Positioning

Options Market

Implied Move

±16.03%

Historical Avg

±7.3%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±16.0% while IQV has averaged ±7.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

51.6%

Calls (204K)P/C Ratio: 0.32Puts (69K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If IQVIA beats expectations, history suggests a stock increase of around 2.48%, confirming the company's strong operational performance.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

A miss could lead to a decline in stock price, with historical data suggesting an average drop of around 4.01%.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$50,001.00–$100,000.00

disclosed dollar ranges

Most Active Members

R-OKKevin HernRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new data analytics partnerships and their expected impact on revenue.
2Any commentary on market trends affecting the life sciences sector.
3Insights into cost management strategies and their effect on margins.
4Discussion of future growth initiatives and areas of investment.
5Management's outlook on competitive pressures and how they plan to address them.